

People

Appointments

Acambis appoints Gordon Cameron as CEO

Following an extensive international search, Acambis (<http://www.acambis.com>) have recently announced that Gordon Cameron is to take up the post of Chief Executive Officer with immediate effect. Cameron began his career at Acambis with his appointment in 1996 as Chief Financial Officer. He took on the additional responsibilities of President of Acambis' US division in 2001, at which time he moved from Cambridge, UK, to Cambridge, USA.

Cameron's move to the USA was at a time of major growth for the company and he was awarded an OBE in the 2004 New Year's Honours list for his services to British biotechnology in the United States. The chairman of Acambis, Alan Smith, commented that: 'The Board appointed international recruitment consultants to undertake a thorough search for candidates to become the new CEO of Acambis. I, and my colleagues on the Board, are delighted that Gordon proved to be the best individual for the job.'

In reply, Cameron said: 'I am delighted to be able to lead Acambis into the next stage of its development and look forward to working with the Board and my excellent management team in building Acambis into one of the world's leading vaccine companies.'

Leslie J. Williams is the new COO of Ventaira Pharmaceuticals

Ventaira Pharmaceuticals (<http://www.ventaira.com>) recently announced the appointment of Leslie J. Williams as Chief Operating Officer. Williams replaced Charles J. Bramlage following his resignation in September 2003, taking the post of Acting COO.

Williams has been with Ventaira since March 2003, taking the post of Vice President, Commercial Development, with responsibility for the development and commercialization of products based

around their proprietary Mystic™ drug inhalation technology. Williams has a broad experience, gained from her time as a critical care nurse and positions in big pharma with Merck and GSK. She obtained her MBA from Washington University, John Olin School of Business.

Ventaira's Chairman, Morton Collins stated: 'Leslie brings over 16 years' commercial experience in the healthcare industry with expertise in successful product launches. Her leadership will guide the development of a new operating strategy that will enable the company to achieve commercial success with their first proprietary asthma product.'

Oxxon Pharmccines appoint Frank Malinoski as CMO

Oxxon Pharmccines (<http://www.oxxonpharmccines.com>) have announced the appointment of Frank Malinoski as Executive Vice President of Development and Chief Medical Officer. Malinoski has over 18 years of experience obtained from many positions, most notably with Wyeth Vaccines, Nabi and as a Clinical Investigator with the US Army Medical Research Institute for Infectious Diseases.

Deirdre Gillespie, Oxxon's President and CEO commented: 'Frank brings a wealth of knowledge and experience to Oxxon at a time when we are driving our two Phase II immunotherapeutic programs forward and expanding our clinical pipeline'.

Malinoski said: 'I am delighted to join the Oxxon team. This team has pioneered the concept of heterologous PrimeBoost technology and stands poised with a robust intellectual property portfolio and an excellent staff to make significant contributions to therapeutic vaccine intervention in the control of chronic infectious diseases and cancer.'

Malinoski has been involved with the successful launch of a number of significant therapeutic vaccines. These include PREVNAR®, for paediatric pneumococcal infection and Meningitec®

and Tetramune® during his time at Wyeth. Whilst at Nabi, he made significant contribution to the development of StaphVax™.

Chronogen announces the appointment of two new VPs

Chronogen (<http://www.chronogen-inc.com>) of Montreal, Canada, recently announced the appointments of Marie-Lise Gauthier, MBA, and Maha Katabi, as Vice Presidents of Finance and Business Development, respectively. Gauthier has significant experience gained in corporate finance of companies involved in telecommunications and consumer/industrial products. Katabi, until recently, held the post of Executive Director within Chronogen, with responsibilities for business development and intellectual property management.

Iraj Beheshti, President and CEO of Chronogen commented that: 'With these nominations, we continue to build a strong and complementary management team' adding that, 'In addition, we will appoint prominent professionals from industry and academia to our Boards of Director and Scientific Advisory Board in the next few months'.

Gauthier obtained an MBA degree from Insead in addition to an industrial engineering degree from Ecole Polytechnique de Montreal. Katabi holds a PhD in Pharmacology from McGill University, where her research interests centred on the development of gene-based therapies for cancer.

Chronogen is involved in the identification of targets related to degenerative processes of aging. In particular, the company is developing novel products to control lipid and oxidative stress levels, which might be significant for the treatment of cardiovascular disorders.

People was written by
Steve Carney